What Adjuvant Capital does

Adjuvant Capital is a US-domiciled venture capital firm (Adjuvant Capital, L.P.) founded in 2018 by Glenn Rockman, previously Managing Partner of the Global Health Investment Fund (GHIF). The firm deploys a $300 million fund — its primary product, the Adjuvant Global Health Technology Fund — making preferred equity investments in life science technologies that have demonstrated safety and efficacy in humans at Phase II or later. Target indications are concentrated in neglected infectious diseases (HIV/AIDS, tuberculosis, malaria, tropical diseases), antimicrobial resistance, pandemic threats, maternal and child health, nutrition, and reproductive and sexual health, with deployment weighted toward low- and middle-income country populations. The firm is headquartered in New York with an additional office in Zurich, Switzerland.

The firm's business model follows standard venture capital mechanics: management fees on assets under management plus carried interest from successful portfolio exits, targeting double-bottom-line returns that combine financial performance with measurable public health impact (SDG 3). The fund's capital base is anchored by strategic limited partners spanning pharmaceutical majors (Novartis, Merck), development finance institutions (IFC, KfW, BII, BMZ), and major foundations (Gates Foundation, Ford Foundation, MacArthur Foundation, Dalio Philanthropies), reflecting an institutional-only investor base. Adjuvant manages a portfolio of more than 20 companies across vaccines, therapeutics, diagnostics, and nutrition, with realized exits including Themis (acquired by Merck), AN2 Therapeutics (acquired by Merck), and Codagenix (Nasdaq-listed).

Operationally, Adjuvant operates a lean team (11-50 headcount) combining founding partners with deep VC and global-health pedigree (Rockman, Kabeer Aziz, Philippe Dro), a Head of Operations and Impact (David Washer), outsourced finance and compliance (Evelyn Yanatos), and a deep bench of senior advisors and venture partners with operating experience at Merck, Novartis Vaccines, VIR Biotechnology, Editas Medicine, Gates Foundation, FDA, and CDC. The firm is a signatory to the Operating Principles for Impact Management, independently verified by BlueMark.

Name

Adjuvant Capital

Legal name

Adjuvant Capital, L.P.

Website

https://adjuvantcapital.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

11–50 employees

Short description

Adjuvant Capital is a New York-based venture capital firm managing a $300 million fund that invests in Phase II-or-later life science technologies addressing neglected infectious diseases, maternal and child health, nutrition, and reproductive health for low- and middle-income country populations.

Ownership category

akta.pro rank

Product category

Venture Capital / Impact Investing

NAICS

Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Infectious Disease & Pandemic Preparedness Vaccines (emerging pathogens) (HLAAAEAC)

akta.pro secondary industries

Vaccine Clinical Development & Regulatory Affairs (HLAIAEAM), Clinical Development & Regulatory for Vaccines (trials, pharmacovigilance, lot release) (HLAAAEAK)

Keywords

• Venture capital financing
• Global health investment
• Life sciences investment
• Impact investing fund
• Neglected disease funding

Headquarters

HQ city

New York

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Others

Revenue model

1. Venture Capital Fund Management: Adjuvant Capital generates returns through traditional venture capital mechanisms including management fees on assets under management and carried interest from successful portfolio company exits. The firm targets double-bottom-line returns combining financial returns with measurable social impact in global health.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Core offering

Adjuvant Capital operates the Global Health Technology Fund, a venture capital vehicle that makes preferred equity investments in life science companies developing vaccines, therapeutics, diagnostics, and health technologies. The firm targets innovations addressing high-burden and neglected infectious diseases, maternal and child health, nutrition, and reproductive/sexual health primarily for low- and middle-income countries, with most investments in technologies that have demonstrated human safety and efficacy at Phase II or later.

Product overview

Adjuvant Capital is a venture capital firm, not a traditional product company. The firm operates the Adjuvant Global Health Technology Fund, which makes preferred equity investments in life science technologies that have demonstrated safety and efficacy in humans. The fund focuses on companies addressing high-burden and neglected infectious diseases (HIV/AIDS, tuberculosis, malaria, tropical diseases), pandemic threats, antimicrobial resistance, maternal and child health, nutrition, and reproductive and sexual health. The portfolio includes investments in vaccine development companies, therapeutic companies, diagnostics platforms, and nutritional product companies.

Differentiator

Problem solved

Functional benefit

Products and services

• Adjuvant Global Health Technology Fund A venture capital fund that makes preferred equity investments in life science companies developing vaccines, therapeutics, diagnostics, and health technologies for neglected infectious diseases, maternal and child health, nutrition, and reproductive/sexual health in low- and middle-income countries. Targeted at institutional LPs (pharmaceutical companies, development finance institutions, foundations, and family offices) seeking double-bottom-line financial and social returns.

Quantifiable outcome

• Investments reached over one million people with essential health interventions in 2024 alone (portfolio company Mamotest)
• +1 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Two partnerships are on record, tiered supporting.

• BlueMarksupportingOthersIndependent verification firm engaged to assess alignment of Adjuvant Capital's impact management system with the Operating Principles for Impact Management.
• Operating Principles for Impact ManagementsupportingOthersAdjuvant Capital is a signatory to the Impact Principles, committing to integrate impact considerations into investment decision-making and disclosure.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Global Health Investment Fund (GHIF): Adjuvant Capital's predecessor platform at J.P. Morgan, GHIF runs an impact-mandated life-sciences investment vehicle targeting neglected diseases and global health. Same thesis, same originating team lineage, and the most direct comparable in structure and mandate.
• RA Capital Management: Boston-based life-sciences crossover fund that co-led VitriVax's Series B alongside Adjuvant. Comparable in life-sciences focus with co-investment partnership evidence and overlapping global-health deal flow.
• Anthos Fund & Asset Management: Asset manager investing in biotech and life sciences with an LP relationship with Adjuvant. Comparable in deploying institutional capital into therapeutic platforms, with overlap on pharma-backed venture themes.

Broad incumbents

• Wellcome Trust (Investment Division): Large charitable foundation with a significant investment portfolio that includes direct equity stakes in biotech and global-health companies. Operates at much greater scale than Adjuvant but shares the global-health mandate and ability to back early-stage life-sciences ventures with patient capital.
• International Finance Corporation (IFC): World Bank Group development finance institution and an Adjuvant LP. IFC runs direct equity and venture programs in emerging-market healthcare and life sciences, sharing both LP and co-investor characteristics with Adjuvant's emerging-markets thesis.
• Bayer Leaps by Bayer: Strategic venture arm of Bayer focused on breakthrough life-sciences technologies including cell/gene therapy and agricultural biotech. Operates as a strategic pharma investor with comparable depth of scientific diligence and global-health adjacency.
• Pfizer Ventures: Strategic corporate venture arm of Pfizer investing in early-stage life-sciences companies. Comparable in deploying pharma balance-sheet capital into therapeutic platforms with potential strategic relevance to global-health indications.

Regional players

• BII (British International Investment): UK development finance institution investing across African and South-Asian healthcare and life-sciences ventures. BII is an Adjuvant LP and operates overlapping emerging-market healthcare investment strategies.
• KfW Development Bank: German development bank investing in emerging-market life sciences and global health. An Adjuvant LP with comparable development-finance mandate and emerging-market deal flow.

Others

• CEPI (Coalition for Epidemic Preparedness Innovations): Global partnership financing vaccine development against emerging infectious disease threats. Adjacent as a non-dilutive capital provider that frequently co-funds Adjuvant's portfolio vaccine companies, shaping the same pandemic-preparedness deal ecosystem.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/adjcap
• LinkedInlinkedin.com/in/grockman

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments35 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Adjuvant Capital